Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
117
datasets available to search
ShareScore release 0.9.0
Dataset results
117 results for “choroidal neovascularization”
Analysis on Multimodal Imaging of 'stealth' Choroidal Neovascularization in Central Serous Chorioretinopathy
<p><strong>Purpose:</strong> To investigate the prevalence of concurrent choroidal neovascularization (CNV) in patients with clinically diagnosed of central serous chorioretinopathy (CSC) and analyze the multimodal imaging characteristics of CSC with ‘stealth’ CNV (CSC-sCNV). <strong>Design: </strong>Retrospective, observational cross-sectional study. <strong>Methods</strong><strong>:</strong> The current study analyzed the clinical data of 111 clinically diagnosed of CSC patients (134 eyes) who received fluorescein fundus angiography (FFA), indocyanine green angiography (ICGA), and optical coherence tomography angiography (OCTA) at their initial visit. The CSC-CNV that can be detected by FFA+ICG was defined as classic CSC-CNV (CSC-cCNV), and CSC-CNV that cannot be detected by FFA+ICG but can be detected by OCTA was defined as CSC-sCNV. The multimodal imaging characteristics of CSC-sCNV were analyzed.<strong> Results: </strong>The concurrent CNV was found in 29 eyes (21.6%) of 28 patients (25.2%), who were significantly older than those without CNV (P=0.039). Among the 29 eyes, 6 eyes (20.7%) were CSC-cCNV and 23 (79.3%) were CSC-sCNV. All CSC-sCNV eyes were type 1 CNV, of which, 22 had photoreceptor layer defects of varying severities. OCTA showed 4 (17.4%) were active CNV and 19 (82.6%) were inactive CNV based on the morphology features. CSC-sCNV lesions manifested as smoke-stack leakage, diffuse RPE changes with/without ink-blot leakage and normal fluorescence on FFA (1 eye, 7 eyes, 10 eyes and 5 eyes respectively). ICGA showed no typical CNV features in CSC-sCNV but choroidal vasodilation beneath CNV lesions and choroidal hyperpermeability at the posterior pole.<strong> Conclusion:</strong> CSC-sCNV may be the primary phenotype of CSC-CNV and its inactivity might be the reason that it cannot be detected by FFA.</p>
A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)
ClinicalTrials.gov study NCT02484690. IPD Sharing: Not stated. Countries: 1. Publications: 4.
Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia
ClinicalTrials.gov study NCT01217944. IPD Sharing: Not stated. Countries: 20. Publications: 2.
A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia.
ClinicalTrials.gov study NCT02034006. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Ranibizumab in Hemorrhagic Choroidal Neovascularization Trial
ClinicalTrials.gov study NCT00363168. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Short-term Efficacy of Intravitreal Afilibercept Depending on Subtypes of Polypoidal Choroidal Vasculopathy: Polypoidal Choroidal Neovascularization or Idiopathic Choroidal Vasculopathy
ClinicalTrials.gov study NCT02597855. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Indocyanine Angiographic Changes of Choroidal Neovascularization by Ranibizumab
ClinicalTrials.gov study NCT01810042. IPD Sharing: Not stated. Countries: 1. Publications: 4.
Safety and Efficacy of Ranibizumab in Japanese Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration
ClinicalTrials.gov study NCT00284089. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization
ClinicalTrials.gov study NCT00436553. IPD Sharing: Not stated. Countries: 2. Publications: 1.
Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)
ClinicalTrials.gov study NCT00433017. IPD Sharing: Not stated. Countries: 12. Publications: 2.
ApoM-bound S1P acts via endothelial S1PR1 to suppress choroidal neovascularization and vascular leak
Open the record for dataset details and reuse information.
Data from: Low incidence of choroidal neovascularization following subthreshold diode micropulse laser (SDM) in high-risk AMD
Purpose: To determine the incidence of new choroidal neovascularization (CNV) in eyes with dry age-related macular degeneration (AMD) following subthreshold diode micropulse laser (SDM). Method: In an observational retrospective cohort study, the records of all patients active in the electronic medical records database were reviewed to identify eyes with dry AMD treated with SDM. Identified eyes were classified by simplified AREDS categories, and analyzed for the primary endpoint of new CNV after treatment. Results: The EMR revealed SDM was offered to 373/392 (95%) patients with dry AMD and elected by 363/373 (97%) between 2008-2017. Follow up was available for 354/363 patients (547 eyes, 98%) (range 6-108 mos., avg. 22). CNV risk factors included age (median 84 years, 67% > 80); reticular pseudodrusen (214 eyes, 39%); AREDS category (78% category 3 and 4); and fellow eye CNV (128 eyes, 23%). New CNV developed in 9/547 eyes (1.6%, annualized rate 0.87%). Visual acuity was unchanged. There were no adverse treatment effects. Summary: In a review of a large group of eyes with exceptionally high-risk AMD, SDM was followed by a very low incidence of new CNV. If confirmed by further study, SDM would offer a new and highly effective treatment to reduce the risk of vision loss from AMD.
Biomarkers and Choroidal Neovascularization
ClinicalTrials.gov study NCT04439708. IPD Sharing: Not stated. Countries: 1. Publications: 4.
Dosing Strategy of Intravitreal Ranibizumab for Pathological Myopia Choroidal Neovascularization
ClinicalTrials.gov study NCT03042871. IPD Sharing: UNDECIDED. Countries: 1. Publications: 14.
Characterization of Early Markers of Choroidal Neovascularization
ClinicalTrials.gov study NCT00801541. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Intravitreal Adalimumab in Refractory Diabetic Retinopathy, Choroidal Neovascularization or Uveitis: A Pilot Study
ClinicalTrials.gov study NCT00855608. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Ranibizumab to Treat Choroidal Neovascularization (CNV) in Patients With Pseudoxanthoma Elasticum (PXE)
ClinicalTrials.gov study NCT00510965. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Dose Escalation Trial of an Intravitreal Injection of Sirna-027 in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)
ClinicalTrials.gov study NCT00363714. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study of rhuFab V2 (Ranibizumab) in Subjects With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)
ClinicalTrials.gov study NCT00090623. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Comparative Study With Photodynamic Therapy And Triamcinolone Versus Photodynamic Therapy, Triamcinolone And Ranibizumab In Patients With Subfoveal Choroidal Neovascularization
ClinicalTrials.gov study NCT00930189. IPD Sharing: Not stated. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.